Akebia Therapeutics (AKBA) Assets Average (2014 - 2026)

Akebia Therapeutics (AKBA) has 13 years of Assets Average data on file, last reported at $369.5 million in Q1 2026.

• On a quarterly basis, Assets Average rose 39.23% year-over-year to $369.5 million in Q1 2026; TTM through Mar 2026 was $369.5 million, a 39.23% increase from a year earlier, with the FY2025 full-year figure at $298.6 million, up 29.17% from the prior year.
• Assets Average for Q1 2026 stood at $369.5 million, roughly flat from $370.4 million in the prior quarter.
• Over the last five years, Assets Average for AKBA reached as high as $535.8 million in Q2 2022 and fell as low as $213.7 million in Q3 2024.
• Historically, Assets Average has averaged $329.4 million across 5 years, with a median of $318.5 million in 2023.
• Across the five-year window, Assets Average sank 50.11% in 2023 and soared 73.14% in 2025, its largest moves.
• Year by year, Assets Average stood at $400.2 million in 2022, then plunged by 40.44% to $238.4 million in 2023, then slipped by 10.26% to $213.9 million in 2024, then surged by 73.14% to $370.4 million in 2025, then slipped by 0.22% to $369.5 million in 2026.
• Per Business Quant data, the three most recent Assets Average figures were $369.5 million in Q1 2026, $370.4 million in Q4 2025, and $354.9 million in Q3 2025.